Vera Therapeutics, Inc. (VERA)

Market Cap	2.90B
Revenue (ttm)	n/a
Net Income (ttm)	-134.38M
Shares Out	63.32M
EPS (ttm)	-2.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,429
Open	46.11
Previous Close	45.90
Day's Range	44.97 - 46.28
52-Week Range	12.28 - 51.61
Beta	1.02
Analysts	Strong Buy
Price Target	54.33 (+18.75%)
Earnings Date	Nov 7, 2024

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Forecast

According to 9 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price forecast is $54.33, which is an increase of 18.75% from the latest price.

Price Target

$54.33

(18.75% upside)

Analyst Consensus: Strong Buy